Autolus Therapeutics plc Quarterly Net Income (Loss) Attributable to Parent in USD from Q4 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Autolus Therapeutics plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q4 2017 to Q3 2024.
  • Autolus Therapeutics plc Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$82.1M, a 79.1% decline year-over-year.
  • Autolus Therapeutics plc Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2024 was -$270M, a 70.9% decline year-over-year.
  • Autolus Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2023 was -$208M, a 40% decline from 2022.
  • Autolus Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2022 was -$149M, a 4.75% decline from 2021.
  • Autolus Therapeutics plc annual Net Income (Loss) Attributable to Parent for 2021 was -$142M, a 0% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$270M -$82.1M -$36.2M -79.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 -$234M -$58.3M -$12.7M -27.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$221M -$52.7M -$12.9M -32.4% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-08
Q4 2023 -$208M -$77.2M -$50.2M -186% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$158M -$45.8M -$3.08M -7.21% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 -$155M -$45.6M -$3.49M -8.31% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$152M -$39.8M -$2.75M -7.42% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-08
Q4 2022 -$149M -$27M Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$42.8M Jul 1, 2022 Sep 30, 2022 10-K 2024-03-21
Q2 2022 -$42.1M Apr 1, 2022 Jun 30, 2022 10-K 2024-03-21
Q1 2022 -$37.1M -$3.8M -11.4% Jan 1, 2022 Mar 31, 2022 10-K 2024-03-21
Q1 2021 -$145M -$33.3M -$3.39M -11.4% Jan 1, 2021 Mar 31, 2021 6-K 2021-05-06
Q4 2020 -$142M -$42.9M -$1.92M -4.68% Oct 1, 2020 Dec 31, 2020 20-F 2023-03-07
Q3 2020 -$140M -$37.3M -$10.1M -36.9% Jul 1, 2020 Sep 30, 2020 6-K 2020-11-05
Q2 2020 -$130M -$32M -$3.57M -12.5% Apr 1, 2020 Jun 30, 2020 6-K 2020-08-06
Q1 2020 -$127M -$29.9M -$2.69M -9.91% Jan 1, 2020 Mar 31, 2020 6-K 2021-05-06
Q4 2019 -$124M -$40.9M -$20.3M -98.3% Oct 1, 2019 Dec 31, 2019 20-F 2022-03-10
Q3 2019 -$104M -$27.2M -$14.4M -112% Jul 1, 2019 Sep 30, 2019 6-K 2020-11-05
Q2 2019 -$89.2M -$28.5M -$20.8M -272% Apr 1, 2019 Jun 30, 2019 6-K 2020-08-06
Q1 2019 -$68.3M -$27.2M -$10.5M -62.6% Jan 1, 2019 Mar 31, 2019 6-K 2020-08-06
Q4 2018 -$57.9M -$20.6M -$13.1M -174% Oct 1, 2018 Dec 31, 2018 20-F 2021-03-04
Q3 2018 -$44.8M -$12.9M Jul 1, 2018 Sep 30, 2018 6-K 2019-11-07
Q2 2018 -$7.65M Apr 1, 2018 Jun 30, 2018 6-K 2019-08-08
Q1 2018 -$16.7M Jan 1, 2018 Mar 31, 2018 6-K 2019-08-08
Q4 2017 -$7.52M Oct 1, 2017 Dec 31, 2017 20-F 2019-02-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.